JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial

Journal:

Cancer Cell

Published:

2026-04-23

DOI:

10.1016/j.ccell.2026.03.018

Affiliations:

20

Authors:

34

Go to article

Institutions	Authors	Share
Sun Yat-sen University Cancer Center (SYSUCC), SYSU, China	8.000000	0.24
Guangzhou Joyo Pharma Co., LTD, China	5.500000	0.16
Shandong Cancer Hospital, China	2.000000	0.06
Chongqing Medical University (CQMU), China	2.000000	0.06
Guangxi Medical University, China	2.000000	0.06
Henan Cancer Hospital, ZZU, China	1.000000	0.03
Fujian Medical University, China	1.000000	0.03
Jilin Province Cancer Hospital, China	1.000000	0.03
Hunan Cancer Hospital, China	1.000000	0.03
Sichuan Cancer Hospital, China	1.000000	0.03
Peking University (PKU), China	1.000000	0.03
Zhejiang Cancer Hospital (ZJCH), China	1.000000	0.03
Shanxi Cancer Hospital, China	1.000000	0.03
Xiangyang Central Hospital, China	1.000000	0.03
Gansu Provincial Cancer Hospital / Gansu Provincial Academic Instiute for Medical Research, China	1.000000	0.03
Jiangxi Provincial Cancer Hospital, China	1.000000	0.03
The First Affiliated Hospital, Zhejiang University School of Medicine, China	1.000000	0.03
Tongji Medical College, HUST, China	1.000000	0.03
The First Affiliated Hospital of Xinxiang Medical University, China	1.000000	0.03
Hangzhou Chengbang Pharmaceutical Technology Co., Ltd, China	0.500000	0.01

Interested in Oncology and Carcinogenesis?